评估预防性干预的获益与负担:结直肠癌筛查的因果框架
本文提出基于半竞争风险疾病-死亡模型的因果框架,用于权衡癌症预防干预的获益与负担。模拟显示所提估计量无偏且推断稳健;应用于妇女健康倡议结直肠癌筛查数据发现,50岁起始筛查以可接受的增量负担-获益比获得最高生命年增益。
要点
- 半竞争风险疾病-死亡模型可因果评估预防干预的获益与负担。
- 模拟显示所提估计量无偏且推断稳健。
- 50岁起始结直肠癌筛查生命年增益最高,增量负担-获益比可接受。
核心结论
- 50岁起始结直肠癌筛查相比不筛查获得最高生命年增益,且增量负担-获益比可接受。
研究设计与样本
- 提出基于半竞争风险疾病-死亡模型的因果框架,并用大量模拟评估估计量性质。
- 应用该框架于妇女健康倡议大型数据,对结直肠癌预防筛查进行获益-负担分析。
主要发现
- 模拟显示所提估计量无偏,且在实际场景中推断稳健。
- 在妇女健康倡议数据中,50岁起始筛查相比不筛查生命年增益最高,增量负担-获益比可接受。
临床怎么用
- 该因果框架可借助大规模观察数据实证评估预防干预的获益与负担权衡。
- 分析结果可为预防性癌症干预提供真实世界证据,辅助确定干预起始时机。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cancer prevention is recognized as a key strategy for reducing disease incidence, mortality, and the overall burden on individuals and society. However, determining when to begin preventive interventions presents a significant challenge: starting too early may lead to more interventions and increased lifetime burdens due to repeated administrations, while delaying may miss opportunities to prevent cancer. Evidence-based recommendations require a benefit-burden analysis that weighs life-years gained against the burden of interventions. With the growing availability of large-scale observational data, there is now an opportunity to empirically evaluate these trade-offs. In this paper, we propose a causal framework for assessing the benefit and burden of cancer prevention, using an illness-death model with semi-competing risks. Extensive simulations demonstrate that the proposed estimators are unbiased, with robust inference across realistic scenarios. We apply this approach to a benefit-burden analysis of the preventive screening for colorectal cancer, utilizing data from the large-scale Women's Health Initiative. Our findings suggest that initiating screening at age 50 years achieves the highest life-year gains with an acceptable incremental burden-to-benefit ratio compared to no screening, contributing valuable real-world evidence to the field of preventive cancer interventions.
引用
- Xiong Y, Chan KCG, Gorfine M, et al. Assessing the Benefits and Burdens of Preventive Interventions. Stat Med. 2026. PMID: 41641624. doi:10.1002/sim.70410
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。